Immunotherapies of systemic lupus erythematosus: Innovations and perspectives;Immunothérapies du lupus systémique: Innovations et perspectives

Revue du Rhumatisme (Edition Francaise)

Volumn 72, Issue 6, 2005, Pages 572-591

  Sibilia, Jean ^a   Sordet, Christelle ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Biologicals; Immunotherapy; Systemic lupus erythematosus; Treatment

Indexed keywords

CD40 LIGAND; COMPLEMENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; RITUXIMAB;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; B LYMPHOCYTE ACTIVATION; COMPLEMENT ACTIVATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LEUKOCYTE ADHERENCE INHIBITION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 20444375487     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.12.014     Document Type: Article

References (250)

1. A.J. Coyle, and J.C. Gutierrez-Ramos More negative feedback? Nat. Immunol. 4 2003 647 648
2. J.M. Kremer, R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, and S. Steinfeld Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4-Ig N. Engl. J. Med. 349 2003 1907 1915
3. D.I. Daikh, and O. Wofsy Cutting edge. Reversal of murine lupus nephritis with CTLA4-Ig and cyclophosphamide J. Immunol. 166 2001 2913 2916
4. M. Takiguchi, M. Murakami, I. Nakagawa, I. Saito, A. Hashimoto, and T. Uede CTLA4-IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice Life Sci 66 2000 991 1001
5. B. Vanhove, G. Laflamme, F. Coulon, M. Mougin, P. Vusio, and F. Haspot Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody Blood 102 2003 564 570
6. B. Diamond, J. Bluestone, and D. Wofsy The immune tolerance network and rheumatic disease: immune tolerance comes to the clinic Arthritis Rheum. 44 2001 1730 1735
7. A.C. Grammer, and P.E. Lipsky CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuels and persons with systemic lupus Arthritis Rheum. 46 2002 1417 1429
8. T. Higuchi, Y. Aiba, T. Nomura, J. Matsuda, K. Mochida, and M. Suzuki Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like auto-immune disease J. Immunol. 168 2002 9 12
9. M.J. Yellin, V. D'Agati, G. Parkinson, A.S. Han, A. Szema, and D. Baum Immunohistologic analysis of renal CD40 and CD40 ligand expression in lupus nephritis and other glomerulonephritides Arthritis Rheum. 40 1997 124 134
10. S.A. Quezada, M. Eckert, O.A. Adeyi, A.R. Schned, R.J. Noelle, and C.M. Burns Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis Arthritis Rheum. 48 2003 2541 2554
11. C. Mohan, Y. Shi, J.D. Laman, and S.K. Datta Interaction between CD40 and its ligand gp39 in the developement of lupus nephritis J. Immunol 154 1995 1470 1480
12. D.I. Daikh, B.K. Finck, P.S. Linsley, D. Hollenbaugh, and D. Wofsy Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways J. Immunol. 159 1997 3104 3108
13. S.L. Kalled, A.H. Cutler, S.K. Datta, and D.W. Thomas Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function J. Immunol. 160 1998 2158 2165
14. G.S. Early, W. Zhao, and C.M. Burns Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of NZB x NZW mice. Response correlates with the absence of an anti-antibody response J. Immunol. 157 1996 3159 3164
15. X. Wang, W. Huang, M. Mihara, J. Sinha, and A. Davidson Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus J. Immunol. 168 2002 2046 2053
16. P. Brams, A. Black, E.A. Padlan, K. Hariharan, J. Leonard, and K. Chambers-Slater A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation Int. Immunopharmacol. 1 2001 277 294
17. J.C. Davis Jr., M.C. Totoritis, J. Rosenberg, T.A. Sklenar, and D. Wofsy Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus J. Rheumatol. 28 2001 95 101
18. A.C. Grammer, R. Slota, R. Fischer, H. Gur, H. Girschick, and C. Yarboro Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions J. Clin. Invest. 112 2003 1506 1520
19. G. Kelsoe Therapeutic CD154 antibody for lupus: promise for the future? J. Clin. Invest. 112 2003 1480 1482
20. W. Huang, J. Sinha, J. Newman, B. Reddy, L. Budhai, and R. Furie The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus Arthritis Rheum. 46 2002 1554 1562
21. D.T. Boumpas, R. Furie, S. Manzi, G.G. Illei, D.J. Wallace, and D.J. Balow A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Dimitrios T Arthritis Rheum. 48 2003 719 727
22. K.C. Kalunian, J.C. Davis Jr., J.T. Merrill, M.C. Totoritis, and D. Wofsy IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial Arthritis Rheum. 46 2002 3251 3258
23. P. Andre, K.S. Prasad, C.V. Denis, M. He, J.M. Papalia, and R.O. Hynes CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism Nat Med 8 2002 247 252
24. T. Kawai, D. Andrews, R.B. Colvin, D.H. Sachs, and A.B. Cosimi Thromboembolic complications alter treatment with monoclonal antibody against CD40 ligand Nat Med 6 2000 114
25. X. Wang, W. Huang, M. Mihara, J. Sinha, and A. Davidson Mechanism of action of combined short term CTLA4-1g and anti-CD40 ligand in murine systemic lupus erythematosus J. Immunol. 168 2002 2046 2053
26. J. Sibilia, and C. Sordet Le rituximab: une bioth́rapie originale dans les maladies auto-immunes Rev. Med. Int. 2005 (sous presse)
27. C. Joao, B.M. Ogle, C. Gay-Rabinstein, J.L. Platt, and M. Cascalho B cell-dependent TCR diversification J Immunol 172 2004 4709 4716
28. R. Eisenberg SLE - Rituximab in lupus Arthritis Res. Ther. 5 2003 157 159
29. ®) in SLE Arthritis Rheum. 46 suppl 2002 S289 Abst 717
30. J.H. Anolik, J. Looney, I. Sanz, and F. Young Abnormalities in B lymphocyte signaling in human SLE Arthritis Rheum. 46 suppl 2002 S415
31. J.H. Anolik, D. Campbell, C. Ritchlin, M. Holyst, S. Rosenfeld, and C. Varnis B lymphocyte depletion as a novel treatment for systemic lupus erythematous: phase I/II trial of rituximab (Rituxan) in SLE Arthritis Rheum. 44 Suppl 9 2001 S387
32. M. Leandro, J. Edwards, G. Cambridge, M.R. Ehrenstein, and D.A. Isenberg An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum. 46 2002 2673 2677
33. R. Weide, J. Heymanns, A. Pandorf, and H. Koppler Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Lupus 12 2003 779 782
34. G.P. Fra, G.C. Avanzi, and E. Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus 12 2003 783 787
35. C. Kneitz, M. Wilhem, and H.P. Tony Effective B cell depletion with rituximab in the treatment of auto-immune diseases Immunobiology 206 2002 519 527
36. S. Perrotta, F. Locatelli, A. La Manna, L. Cennamo, P. De Stefano, and B. Nobili Anti-CD20 monoclonal antibody (Rituximab) for life-threatening auto-immune haemolytic anemia in a patient with systemic lupus erythematosus Br. J. Haematol. 116 2002 465 467
37. J.T. Merrill Rituximab in antiphospholipid syndrome Curr. Rheumatol. Rep. 5 2003 381 382
38. R.H. Carter A role for BLyS in tissue inflammation? Arthritis Rheum. 48 2003 882 885
39. J. Zhang, V. Roschke, K.P. Baker, Z. Wang, G.S. Alarcon, and B.J. Fessler Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus J. Immunol. 166 2001 6 10
40. G.S. Cheema, V. Roschke, D.M. Hilbert, and W. Stohl Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases Arthritis Rheum. 44 2001 1313 1319
41. K.P. Baker, B.M. Edwards, S.H. Main, G.H. Choi, R.E. Wager, and W.G. Halpern Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis Rheum. 48 2003 3253 3265
42. D.S. Jones, P.A. Barstad, M.J. Feild, J.P. Hachmann, M.S. Hayag, and K.W. Hill Immunospecific reduction of anti-oligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis J. Med. Chem. 38 1995 2138 2144
43. M.H. Weisman, H.G. Bluestein, C.M. Berner, and H.A. de Haan Reduction in circulating dsDNA antibody titer after administration of LJP 394 J. Rheumatol. 24 1997 314 318
44. R.A. Furie, J.M. Cash, M.E. Cronin, R.S. Katz, M.H. Weisman, and C. Aranow Treatment of systemic lupus erythematosus with LJP 394 J. Rheumatol. 28 2001 257 265
45. D. Alarcon-Segovia, J.A. Tumlin, R.A. Furie, J.D. McKay, M.H. Cardiel, and V. Strand LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study Arthritis Rheum. 48 2003 442 454
46. V. Strand, C. Aranow, M.H. Cardiel, D. Alarcon-Segovia, R. Furie, and Y. Sherrer Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo Lupus 12 2003 677 686
47. D.J. Wallace Apheresis for lupus erythematosus: state of the art Lupus 10 2001 193 196
48. K. Cockerill, M.D. Linnik, D.S. Jones, M. Campbell, M.J. Branks, and G.M. Iverson A novel therapeutic approach for treating antiphospholipid syndrome based on tolerizing anti-β2-GPI B cells Arthritis Rheum. 43 suppl 2002 S230 Abst 537
49. S. Faderl, D.A. Thomas, S. O'Brien, G. Garcia-Manero, H.M. Kantarjian, and F.J. Giles Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood 101 2003 3413 3415
50. J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, and T. Boone Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clin Cancer Res 9 2003 39825 39905
51. T. Lajaunias, A. Ida, S. Kikuchi, L. Fossati-Jimack, F. Martinez-Soria, and T. Moll Diffential control of CD22 ligand expression on B and T lymphocytes and enhanced expression in murine systemic lupus Arthritis Rheum. 48 2003 1612 1621
52. J. Kauffman, W.A. Wegener, J.D. Horpick, M. Qidwai, C. Ding, and M. Elmera Pilot clinical trial of epratuzumab (humanized anti-CD22 antibody) for immuntherapy in systemic lupus erythematous Ann Rheum Dis 63 suppl1 2004 237 (Abst Thu 0443)
53. J.M. Harper, and A. Cook Beneficial effects of non-depleting anti-CD4 in MRL/Mp-lpr/lpr mice with active systemic lupus erythematosus and microscopic angiitis Auto-immunity 33 2001 245 251
54. D. Wofsy, and W.E. Seman Successful treatment of auto-immunity in NZB/NZW F1 mice with monoclonal antibody to L3T4 J. Exp. Med. 161 1985 378 391
55. I. Brink, B. Thiele, G.R. Burmester, G. Trebeljahr, F. Emmerich, and F. Hiepe Effects of anti-CD4 antibodies on the release of IL-6 and TNFalpha in whole blood samples from patients with systemic lups erythematosus Lupus 8 1999 723 730
56. F.J. Stafford, T.A. Fleisher, G. Lee, M. Brown, V. Strand, and H.A. Austin A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus J. Rheumatol. 21 1994 2068 2070
57. K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian-Ruiz, L. Taylor, and D. Donaldson AntiCD3 monoclonal antibody in new-onset type 1 diabetes mellitus N. Engl. J. Med. 346 2002 1692 1698
58. G.M. Han, S.L. Chen, N. Shen, S. Ye, C.D. Bao, and Y.Y. Gu Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray Genes Immun. 4 2003 177 186
59. B.H. Hahn, R.R. Singh, W.K. Wong, B.P. Tsao, K. Bulpitt, and F.M. Ebling Treatment with a consensus peptide based on aminoacid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus Arthritis Rheum. 44 2001 432 441
60. E. Eilat, M. Dayan, H. Zinger, and E. Mozes The mechanisms by which a peptide based on complementarity-determining region-1 of pathogenic anti-DNA autoantibodies ameliorates experimental systemic lupus erythematosus Proc. Natl. Acad. Sci. USA 98 2001 1148 1153
61. A. Faber-Elmann, E. Eilat, H. Zinger, and E. Mozes A peptide based on an anti-DNA autoantibody down regulates matrix-metalloproteinases in murine models of lupus Clin. Immunol. 105 2002 223 232
62. Z.M. Sthoeger, M. Dayan, A. Tcherniack, L. Green, S. Toledo, and R. Segal Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies Clin. Exp. Immunol. 131 2003 385 392
63. F. Spertini, A. Leimgruber, B. Morel, M.B. Khazaeli, K. Yamamoto, and J.M. Dayer Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis J. Rheumatol. 26 1999 2602 2608
64. A. Waisman, P.J. Ruiz, E. Israeli, E. Eilat, S. Konen-Waisman, and H. Zinger Modulation fo murine systemic lupus erythematosus with peptides based on complementary determining regions of a pathogenic anti-DNA monoclonal antibody Proc. Natl. Acad. Sci. USA 94 1997 4620 4625
65. G.C. Fan, and R.R. Singh Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus J. Exp. Med. 196 2002 731 741
66. F.Y. Wu, F.J. Ward, and N.A. Staines Histone peptide-induced nasal tolerance: suppression of murine lupus J. Immunol. 169 2002 1126 1134
67. F. Monneaux, J.M. Lozano, M.E. Patarroyo, J.P. Briand, and S. Muller T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice Eur. J. Immunol. 33 2003 287 296
68. V.M. Holers The complement system as a therapeutic target in auto-immunity Clin. Immunol. 107 2003 140 151
69. Y. Wang, Q. Hu, J.A. Madri, S.A. Rollins, A. Chodera, and L.A. Matis Amelioration of lupus like auto-immune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc. Natl. Acad. Sci. USA 93 1996 8563 8568
70. M.A. Solsky, and D.J. Wallace New therapies in systemic lupus erythematosus Best Pract. Res. Clin. Rheumatol. 16 2002 293 312
71. L. Bao, M. Haas, S.A. Boackle, D.M. Kraus, P.N. Cunningham, and P. Park Transgenic expression of a soluble complement inhibitor protects againts renal disease and promotes survival in MRL/lpr mice J. Immunol. 168 2002 3601 3607
72. V.M. Holers, G. Girardi, L. Mo, J.M. Guthridge, H. Molina, and S.S. Pierangeli Complement C3 activation is required for anti-phospholipid antibody-induced fetal loss J. Exp. Med. 178 2002 166 176
73. C. Xu, D. Mao, V.M. Holers, B. Palanca, A.M. Cheng, and H. Molina A critical role for murine complement regulator crry in fetomaternal tolerance Science 287 2000 498 501
74. A.L. Mellor, J. Sivakumar, P. Chandler, K. Smith, H. Molina, and D. Mao Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy Nat. Immunol. 2 2001 64 68
75. H.W. Snyder Jr., S.K. Cochran, J.P. Balint Jr., J.H. Bertram, A. Mittelman, and T.H. Guthrie Jr. Experience with protein A - immuno-absorption in treatment-resistant adult immune thrombocytopenic purpura Blood 79 1992 2237 2245
76. J.F. Kunkel, R. Sarode, M. Verba, and R. Yomtovian Heparin-induced coagulopathy associated with staphylococcal protein A immunoadsorption treatment columns: an in vitro and in vivo analysis Transfusion 40 2000 697 701
77. G. Samuelsson Extracorporeal immunoadsorption with protein A: technical aspects and clinical results J. Clin. Apheresis 16 2001 49 52
78. H. Kutsuki, S. Takata, K. Yamamoto, and N. Tani Therapeutic selection adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus Ther. Apheresis 2 1998 18 24
79. K. Suzuki, M. Hara, M. Harigai, T. Ishizuka, T. Hirose, and Y. Matsuki Continuous removal of anti-DNA antibody apheresis in systemic lupus erythematosus Lancet 336 1990 753 754
80. M. Gaubitz, M. Seidel, S. Kummer, H. Schotte, A. Perniok, and W. Domschke Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus J. Auto-immun 11 1998 495 501
81. S.E. Pincus, N. Lukacher, N. Mohamed, M. Sesay, R. Zabinski, and R. Ebelle Evaluation of antigen-based heteropolymer for treatment of systemic lupus erythematosus in a non human primate model Clin. Immunol. 105 2002 141 154
82. C. Iking-Konert, S. Stocks, R. Fischer, E. Bleck, R. Engelbrecht, and S. Pincus Evaluation of safety and efficiency of lowering antibodies to dsDNA following a single intravenous administration of the novel monoclonal antibody ETI104 in patients with systemic lupus erythematodes Arthritis Rheum. 46 suppl 2002 S282
83. B. Gaynor, C. Putterman, and P. Valadon Peptide inhibition of glomerular deposition of an anti-DNA antibody Proc. Natl. Acad. Sci. USA 94 1997 1955 1960
84. B. Pfueller, K. Wolbart, A. Bruns, G.R. Burmester, and F. Hiepe Successful treatment of patients with systemic lupus erythematosis by immunoadsorption with a C1q column: a pilot study Arthritis Rheum 44 2001 1962 1963
85. H. Watanabe, D. Sherris, and G.S. Gilkeson Soluble CD16 in the treatment of murine lupus nephritis Clin. Immunol. Immunopathol. 88 1998 91 95
86. M. Napirei, H. Karsunky, B. Zevnik, H. Stephan, H.G. Mannherz, and T. Möröy Features of systemic lupus erythematosus in DNAase1-deficient mice Nat. Genet. 25 2000 177 181
87. A. Wilber, T.P. O'Connor, M.L. Lu, A. Karimi, and M.C. Schneider Dnase1l3 deficiency in lupus-prone MRL and NZB/W F1 mice Clin. Exp. Immunol. 134 2003 46 52
88. E. Balada, J. Ordi-Ros, S. Hernanz, J. Villarreal, F. Cortes, and M. Vilardell-Tarres DNAase I mutation and systemic lupus erythematosus in a Spanish population: comment on the article by Tew et al Arthritis Rheum 46 2002 1974 1976
89. N.B. Tew, R.W. Johnson, J.D. Reveille, and F.K. Tan A molecular analysis of the low serum deoxyribonuclease activity in lupus patients Arthritis Rheum 44 2001 2246 2247
90. K. Yasutomo, T. Horiuchi, S. Kagami, H. Tsukamoto, C. Hashimura, and M. Urushihara Mutation of DNAase 1 in people with systemic lupus erythematosus Nat Genet 28 2001 313 314
91. J.C. Davis Jr., S. Manzi, C. Yarboro, J. Rairie, I. Mcinnes, and D. Averthelyi Recombinant human DNAase I (rhDNAase) in patients with lupus nephritis Lupus 8 1999 68 76
92. S. Berger, R. Chandra, H. Balló, R. Hildenbrand, and H.J. Stutte Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes Eur. J. Immunol. 27 1997 2994 3000
93. M. Linker-Israeli, M. Honda, R. Nand, R. Mandyam, E. Mengesha, and D.J. Wallace Exogenous IL-10 and IL-4 down-regulate IL-6 production by SLE-derived PBMC Clin. Immunol. 91 1999 6 16
94. J. Rönnelid, A. Teijde, L. Mathsson, K. Nilsson-Ekdahl, and B. Nilsson Immune complexes from SLE sera induce IL-10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism: implication for a possible vicious cycle maintaining B cell hyperactivity in SLE Ann. Rheum. Dis. 62 2003 37 42
95. B. Balasa, and K. Sarvetnic Is pathogenic humoral auto-immunity a Th1 response? Lesson from myasthenia grown Immunol. Today 21 2000 19 23
96. B.L. Bermas, M. Petri, D. Goldman, B. Mittleman, M.W. Miller, and N.I. Stocks T helper cell dysfonction in systemic lupus erythematosus: relative to disease activity J. Clin. Immunol. 14 1994 169 177
97. R. Segal, B.L. Bermas, M. Dayan, F. Kalush, G.M. Shearer, and E. Mozes Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of Thelper cell 1/Thelper cell 2 - type cytokines in diseases J. Immunol. 158 1997 3009 3016
98. K. Masutani, M. Akahoshi, and T. Tsuruya Predominance of Th1 immune response in diffuse proliferative lupus nephritis Arthritis Rheum 44 2001 2097 2106
99. V. Pascual, J. Banchereau, and A.K. Palucka The central role of dendritic cells and interferon-alpha in SLE Curr. Opin. Rheumatol. 15 2003 548 556
100. C. Scheinecker, B. Zwölfer, M. Köller, G. Mánner, and J.S. Smolen Alterations of dendritic cells in systemic lupus erythematosus Arthritis Rheum. 44 2001 856 865
101. K. Kato, E. Santana-Sahagun, L.Z. Rassenti, M.H. Weisman, N. Tamura, and S. Kobayashi The soluble CD40 ligand sCD154 in systemic lupus erythematosus J. Clin. Invest. 104 1999 947 955
102. L. Ronnblom, and G.V. Alm A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus J. Exp. Med. 194 2001 1823 1834
103. P. Blanco, A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus Science 294 2001 1540 1543
104. M.A. Gill, P. Blanco, E. Arce, V. Pascual, J. Banchereau, and A.K. Palucka Blood dendritic cells and DC-poietins in systemic lupus erythematosus Hum. Immunol. 63 2002 1172 1180
105. A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, and Z.K. Ballas Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells Eur. J. Immunol. 31 2001 2154 2163
106. S. Blomberg, M.L. Eloranta, B. Cederblad, K. Nordlin, G.V. Alm, and L. Ronnblom Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus Lupus 10 2001 484 490
107. D.G. Millar, K.M. Garza, B. Odermatt, A.R. Elford, N. Ono, and Z. Li Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to auto-immunity in vivo Nat. Med. 9 2003 1469 1476
108. F. Mackay, S.A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, and P. Schneider Mice transgenic for BAFF develop lymphocytic disorders along with auto-immune manifestations J Exp Med. 190 1999 1697 1710
109. M.B. Litinskiy, B. Nardelli, D.M. Hilbert, B. He, A. Schaffer, and P. Casali DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL Nat. Immunol. 3 2002 822 829
110. G. Jego, A.K. Palucka, J.P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 Immunity 19 2003 225 234
111. D. Braun, P. Geraldes, and J. Demengeot Type I Interferon controls the onset and severity of auto-immune manifestations in lpr mice J. Auto-immun 20 2003 15 25
112. T.N. Jorgensen, M.R. Gubbels, and B.L. Kotzin Links between type I interferons and the genetic basis of disease in mouse lupus Auto-immunity 36 2003 491 502
113. M.L. Santiago-Raber, R. Baccala, K.M. Haraldsson, D. Choubey, T.A. Stewart, and D.H. Kono Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice J. Exp. Med. 197 2003 777 788
114. D.H. Kono, R. Baccala, and A.N. Theofilopoulos Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor Auto-immunity 36 2003 503 510
115. M.R. Ehrenstein, E. McSweeney, M. Swane, C.P. Worman, A.H. Goldstone, and D.A. Isenberg Appearance of anti-DNA antibodies in patients treated with interferon-alpha Arthritis Rheum. 36 1993 279 280
116. L.E. Ronnblom, G.V. Alm, and K.E. Oberg Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour J. Intern. Med. 227 1990 207 210
117. Y. Ioannou, and D.A. Isenberg Current evidence for the induction of auto-immune rheumatic manifestations by cytokine therapy Arthritis Rheum. 43 2000 1431 1442
118. U.B. Wandl, M. Nagel-Hiemke, D. May, E. Kreuzfelder, O. Kloke, and M. Kranzhoff Lupus-like auto-immune disease induced by interferon therapy for myeloproliferative disorders Clin. Immunol. Immunopathol. 65 1992 70 74
119. I. Krause, G. Valesini, R. Scrivo, and Y. Shoenfeld Auto-immune aspects of cytokine and anticytokine therapies Am. J. Med. 115 2003 390 397
120. E.C. Baechler, F.M. Batliwalla, G. Karypis, P.M. Gaffney, W.A. Ortmann, and K.J. Espe Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus Proc. Natl. Acad. Sci. USA 100 2003 2610 2615
121. L. Bennett, A.K. Palucka, E. Arce, V. Cantrell, J. Borvak, and J. Banchereau Interferon and granulopoiesis signatures in systemic lupus erythematosus blood J. Exp. Med. 197 2003 711 723
122. M.K. Crow Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum. 48 2003 2396 2401
123. A. Chuntharapai, J. Lai, X. Huang, V. Gibbs, K.J. Kim, and L.G. Presta Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interf́ron: a candidate therapeutic for IDDM and SLE Cytokine 15 2001 250 260
124. M.K. Crow, and J. Wohlgemuth Microarray analysis of gene expression in lupus Arthritis Res. Ther. 5 2003 279 287
125. A. Dzionek, Y. Sohma, J. Nagafune, M. Cella, M. Colonna, and F. Facchetti DCA-2, a novel plasmocytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor if interferon alpha/beta induction J. Exp. Med. 194 2001 59 63
126. K. Honda, T. Mizutani, and T. Ianiguchi Negative regulation of IFN-α/β signaling by IFN regulatory factor-2 for homeostatic development of dendritic cells Proc. Natl. Acad. Sci. USA 101 2004 2416 2421
127. E. Ichikawa, S. Hida, Y. Omatsu, S. Shimoyama, K. Takahara, and S. Miyagawa Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2 Proc. Natl. Acad. Sci. USA 101 2004 3909 3914
128. D.J. Min, M.L. Cho, C.S. Cho, S.Y. Min, W.U. Kim, and S.Y. Yang Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus Scand. J. Rheumatol. 30 2001 159 163
129. J.P. Seery IFN-gamma transgenic mice: clues to the pathogenesis of systemic lupus erythematosus? Arthritis Res. 2 2000 437 440
130. H. Amital, Y. Levi, M. Blank, V. Barak, P. Langevitz, and A. Afek Immunomodulation of murine experimental SLE-like disease by interferon-gamma Lupus 7 1998 445 454
131. D. Balomenos, R. Rumold, and A.N. Theofilopoulos Interferon-gamma is required for lupus-like disease anf lymphoaccumulation in MRL/lpr mice J. Clin. Invest. 101 1998 364 371
132. C. Haas, B. Ryffel, and M. Le Hir IFN-gamma is essential for the developement of auto-immune glomerulonephritis in MRL/lpr mice J. Immunol. 158 1997 5484 5491
133. L. Ozmen, D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, and G. Garotta Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis Eur. J. Immunol. 25 1995 6 12
134. B.R. Lawson, G.J. Prud'homme, Y. Chang, H.A. Gardner, J. Kuan, and D.H. Kono Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc J. Clin. Invest. 106 2000 207 215
135. G.J. Prud'homme Gene therapy of auto-immune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors J. Gene Med. 2 2000 222 232
136. N. Mishra, C.M. Reilly, D.R. Brown, P. Ruiz, and G.S. Gilkeson Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse J. Clin. Invest. 111 2003 539 552
137. P. Chomarat, M.C. Rissoan, J. Banchereau, and P. Miossec Interferon gamma inhibits interleukin 10 production by monocytes J. Exp. Med. 177 1993 523 527
138. B.R. Lauwerys, N. Garot, J.C. Renauld, and F.A. Houssiau Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients Arthritis Rheum. 43 2000 1976 1981
139. L. Llorente, W. Zhou, Y. Levy, Y. Richaud-Patin, J. Wijdenes, and J. Alcocer-Varela Role of interleukin-10 in B lymphocyte hyperactivity and autoantibody production of human specific lupus erythematosus J. Exp. Med. 181 1995 839 844
140. L. Llorente, and Y. Richaud-Patin The role of Interleukin-10 in systemic lupus erythematosus J. Auto-immun 20 2003 287 289
141. F.A. Houssiau, C. Lefebvre, M. Van den Berghe, M. Lambert, J.P. Devogelaer, and J.C. Renauld Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity Lupus 4 1995 393 395
142. A.W. Gibson, J.C. Edberg, J. Wu, R.G. Westendorp, T.W. Huizenga, and R.P. Kimberly Novel single nucleotide polymorphism in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus J. Immunol. 166 2001 3915 3922
143. L. Llorente, Y. Richaud-Patin, C. Garcia-Padilla, E. Claret, J. Jakez-Ocampo, and M.H. Cardiel Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus Arthritis Rheum. 43 2000 1790 1800
144. C. Mauri, D. Gray, N. Mushtaq, and M. Londei Prevention of arthritis by interleukin 10-producing B cells J. Exp. Med. 197 2003 489 501
145. S. Fillatreau, C.H. Sweenie, M.J. McGeachy, D. Gray, and S.M. Anderton B cells regulate auto-immunity by provision of IL-10 Nat. mmunol. 3 2002 944 950
146. J. Tyrrell-Price, P.M. Lydyard, and D.A. Isenberg The effect of interleukin-10 and interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus Clin. Exp. Immunol. 124 2001 118 125
147. K. Balabanian, J. Couderc, L. Bouchet-Delbos, A. Amara, D. Berrebi, and A. Foussat Role of the chemokine stromal cell-derived factor 1 in auto antibody production and nephritis in murine lupus J. Immunol. 170 2003 3392 3400
148. H. Groux, and F. Cottrez The complex role of interleukin-10 in auto-immunity J. Auto-immun 20 2003 281 285
149. D. Yadav, and N. Sarvetnick Cytokines and auto-immunity: redundancy defines their complex nature Curr. Opin. Immunol. 15 2003 697 703
150. W.A. Border, N.A. Noble, T. Yamamoto, J.R. Harper, Y. Yamaguchi, and M.D. Pierschbacher Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease Nature 360 1992 361 364
151. W.A. Border, and E. Ruoslahti Transforming growth factor-beta in disease: the dark side of tissue repair J. Clin. Invest. 90 1992 1 7
152. H. Ishida, T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard Continuous administration of anti-interleukin 10 antibodies delays onset of auto-immunity in NZB/WF1 Mice J. Exp. Med. 179 1994 305 310
153. L. Georgescu, R.K. Vakkalanka, K.B. Elkon, and M.K. Crow Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand J. Clin. Invest. 100 1997 2622 2633
154. A.E. Mongan, S. Ramdahin, and R.J. Warrington Interleukin-10 response abnormalities in systemic lupus erythematosus Scand. J. Immunol. 46 1997 406 412
155. Z. Yin, G. Bahtiyar, and N. Zhang IL-10 regulated murine lupus J. Immunol. 169 2002 2148 2155
156. P. Gergely Jr., B. Niland, N. Gonchoroff, R. Pullmann Jr., P.E. Phillips, and A. Perl Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus J. Immunol. 169 2002 1092 1101
157. Y. Kalechman, U. Gafter, J.P. Da, M. Albeck, D. Alarcon-Segovia, and B. Sredni Delay in the onset of systemic lupus erythematosus following treatement immunomodulator AS101: association with IL-10 inhibition and in TNF-alpha levels J. Immunol. 159 1997 2658 2667
158. T. Fujii, M. Okada, T. Mimori, and J. Craft The transmembrane form of TNF-alpha drives autoantibody production in the absence of CD154: studies using MRL/Mp-Fas(lpr) mice Clin. Exp. Immunol. 130 2002 224 232
159. D. Marshall, J.P. Dangerfield, V.K. Bhatia, K.Y. Larbi, S. Nourshargh, and D.O. Haskard MRL/lpr lupus-prone mice show exaggerated ICAM-1-dependent leucocyte adhesion and transendothelial migration in response to TNF-alpha Rheumatol. 42 2003 929 934
160. Y. Deguchi, and S. Kishimoto Tumour necrosis factor/cachectin plays a key role in auto-immune pulmonary inflammation in lupus-prone mice Clin. Exp. Immunol. 85 1991 392 395
161. T. Zhou, C.K. Edwards 3rd, P. Yang, Z. Wang, H. Bluethmann, and J.D. Mountz Greatly accelerated lymphadenopathy and auto-immune disease in lpr mice lacking tumor necrosis factor receptor I J. Immunol. 156 1996 2661 2665
162. D. Kontoyiannis, and G. Kollias Accelerated auto-immunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor Eur. J. Immunol. 30 2000 2038 2047
163. C. Gordon, G.E. Ranges, J.S. Greenspan, and D. Wofsy Chronic therapy with recombinant tumor necrosis factor-alpha in auto-immune NZB/NZW F1 mice Clin. Immunol. Immunopathol. 52 1989 421 434
164. H. Yokoyama, B. Kreft, and V.R. Kelley Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms Kidney Int. 47 1995 122 30
165. R. Segal, M. Dayan, H. Zinger, and E. Mozes Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline Lupus 10 2001 23 31
166. E.A. Green, Y. Choi, and R.A. Flavell Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals Immunity 16 2002 183 191
167. M. Menges, S. Rossner, C. Voigtlander, H. Schindler, N.A. Kukutsch, and C. Bogdan Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from auto-immunity J. Exp. Med. 195 2002 15 21
168. M. Aringer, C. Steiner, W. Graninger, and J.S. Smollen Role of tumor necrosis factor α and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky Arthritis Rheum. 44 2001 1721 1722
169. X. Su, T. Zhou, P. Yang, C.K. Edwards, and J.D. Mountz Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor Arthritis Rheum. 41 1998 139 149
170. C. Gabay, N. Cakir, F. Moral, P. Roux-Lombard, O. Meyer, and J.M. Dayer Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity J. Rheumatol. 24 1997 3030 3308
171. R. Herrera-Esparza, O. Barbosa-Cisneros, R. Villalobos-Hurtado, and E. Avalos-Diaz Renal expression of IL-6 and TNFalpha genes in lupus nephritis Lupus 7 1998 154 158
172. R.A. Mageed, and D.A. Isenberg Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production Lupus 11 2002 850 855
173. A. Studnicka-Benke, G. Steiner, P. Petera, and J.S. Smolen Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and auto-immune activity in systemic lupus erythematosus Br. J. Rheumatol. 35 1996 1067 1074
174. M. Rudwaleit, M. Tikly, M. Khamashta, K. Gibson, J. Klinke, and G. Hughes Interethnic differences in the association of tumor necrosis factor promoter polymorphism with systemic lupus erythematosus J. Rheumatol. 23 1996 1725 1728
175. A.H. Hajeer, J. Worthington, E.J. Davies, M.C. Hillarby, K. Poulton, and W.E. Ollier TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus Tissue Antigens 49 1997 222 227
176. C. Morita, T. Horiuchi, H. Tsukamoto, N. Hatta, Y. Kikuchi, and Y. Arinobu Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosis in the Japanese Arthritis Rheum. 12 2001 2819 2827
177. B. Hostmann, R. Klein, V. Ruppert, C. Johnsen, S. Sethmann, and F. Hiepe Effect of TNF-α on the m RNA expression of the 52 Ro/SS-A autoantigen in human keratinocyte Arthritis Rheum. 44 suppl 2001 S203
178. B. Hostmann, V. Ruppert, and M. Gerl The TNF-α induced upregulation of 52kD Ro/SSA autoantigen expression in human keratinocytes is mediated via TNF-α receptor I (TNF-RI) Arthritis Rheum. 46 suppl 2002 S277
179. A.N. Theofilopoulos, and B.R. Lawson Tumor necrosis factor and other cytokines in murine lupus Ann. Rheum. Dis. 58 1999 49 55
180. E.M. Davas, A. Tsirogianni, I. Kappou, D. Karamitsos, I. Economidou, and P.C. Dantis Serum IL-6, TNF alpha, p55 srTNFalpha, p75srTNFalpha, srlL-2alpha levels and disease activity in systemic lupus erythematosus Clin. Rheumatol. 18 1999 17 22
181. G.S. Bleumink, E.J. ter Borg, C.G. Ramselaar, and S.B. Stricker Etanercept-induced subacute cutaneous lupus erythematosus Rheumatol. 40 2001 1317 1319
182. A.P. Carins, M.K.J. Duncan, A.F. Hinder, and A.J. Taggart New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis Ann. Rheum. Dis. 61 2002 1031 1032
183. M. Shakoor, M. Michalska, C.A. Harris, and J.A. Block Drug-induced systemic lupus erythematosus associated with etanercept therapy Lancet 359 2002 579 580
184. P.J. Charles, R.J.T. Smeek, J. De Jond, M. Feldmann, and R.N. Maini Assessement of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α Arthritis Rheum. 43 2000 2283 2390
185. C. Casciola, L.A. Rosen, G. Anhalt, and A. Rosen Autoantigens targeted in systemic lupus erythematosus are clostered in two population of surface structures on apoptotic keratinocytes J. Exp. Med. 179 1994 1317 1330
186. S.P. Hart, G.J. Dougherty, C. Haslett, and I. Dransfield CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages J. Immunol. 159 1997 919 925
187. M. Herrmann, R.E. Voll, O.M. Zoller, M. Hagenhofer, B.B. Ponner, and J.R. Kalden Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus Arthritis Rheum. 41 1998 1241 1250
188. C.S. Via, A. Shustov, V. Rus, T. Lang, P. Nguyen, and F.D. Finkelman In vivo neutralization of TNF-alpha promotes humoral auto-immunity by preventing the induction of CTL J. Immunol. 167 2001 6821 6826
189. U. Christen, and M.G. Von Herrath Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the auto-immune process is already ongoing Ann. N. Y. Acad. Sci. 958 2002 166 169
190. A.P. Cope, R.S. Liblau, X.D. Yang, M. Congia, C. Laudanna, and R.D. Schreiber Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling J. Exp. Med. 185 1997 1573 1584
191. B. Fautrel, V. Voltz, C. Franc̀s, P. Bourgeois, and S. Rozenberg Regression of subacute cutaneous lupus erythematosus in a patient with rheumatic arthritis treated with a biologic tumor necrosis factor α-blocking agent Arthritis Rheum. 45 2002 1408 1409
192. M. Aringer, C. Zimmermann, W.E. Graninger, P. Petera, S. Stöckl, and G. Steiner TNFα is an essential mediator in lupus nephritis Arthritis Rheum. 46 suppl 2002 441 LB08
193. J.F. Viallard, J.L. Taupin, V. Miossec, J.L. Pellegrin, and B.L. Moreau Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifie LIF as a potentiel marker of disease activity Eur. Cytokine Netw. 10 1999 17 24
194. Y. Tokano, S. Morimoto, H. Kaneko, H. Amano, K. Nozawa, and Y. Takasaki Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation of Th1-and Th2-derived cytokines Clin. Exp. Immunol. 116 1999 169 173
195. T.F. Liu, and B.M. Jones Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes Cytokine 10 1998 140 147
196. F.A. Houssiau, F. Mascart-Lemone, M. Stevens, M. Libin, J.P. Devogelaer, and M. Goldman IL-12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC) Clin. Exp. Immunol. 108 1994 375 380
197. F.P. Huang, G.J. Feng, G. Lindop, D.I. Stott, and F.Y. Liew The role of interleukin 12 and nitric oxide in the development of spontaneous auto-immune disease in MRL/lpr mice J. Exp. Med. 183 1996 1447 1459
198. E. Kikawada, D.M. Lenda, and V.R. Kelley IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology J. Immunol. 170 2003 3915 3925
199. E. Hagiwara, T. Okubo, I. Aoki, S. Ohno, T. Tsuji, and A. Ihata IL-12-encoding plasmid has a beneficial effect on spontaneous auto-immune disease in MRL/MP-lpr/lpr mice Cytokine 12 2000 1035 1041
200. A. Kitani, M. Hara, T. Hirose, K. Norioka, M. Harigai, and W. Hirose Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus Clin. Exp. Immunol. 77 1989 31 36
201. B.K. Finck, B. Chan, and D. Wofsy Interleukin 6 promotes murine lupus in NZB/NZW F1 mice J. Clin. Invest. 94 1994 585 591
202. C.K. Wong, C.Y. Ho, E.K. Li, L.S. Tam, and C.W. Lam Elevated production of interleukin-18 is associated with renal disease patients with systemic lupus erythematosus Clin. Exp. Immunol. 130 2002 345 351
203. P. Amerio, A. Frezzolini, D. Abeni, P. Teofoli, C.R. Girardelli, and O. De Pita Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines Clin. Exp. Rheumatol. 20 2002 535 538
204. J. Faust, J. Menke, J. Kriegsmann, V.R. Kelley, W.J. Mayet, and P.R. Galle Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Fas mice with auto-imune lupus nephritis Arthritis Rheum. 46 2002 3083 3095
205. V.Y. Melnikov, T. Ecder, G. Fantuzzi, B. Siegmund, M.S. Lucia, and C.A. Dinarello Impaired IL-18 processing protects caspase-1-deficient mice from ichemic acute renal failure J. Clin. Invest. 107 2001 1145 1152
206. D.C. Brennan, M.A. Yui, R.P. Wuthrich, and V.E. Kelley Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury J. Immunol. 143 1989 3470 3475
207. H.U. Schorlemmer, E.J. Kanzy, and K.D. Langner Kurrle R. Immunoregulation of SLE-like disease mice and MRL auto-immune mice Agents Actions 39 Suppl 1993 C117 C120
208. ®) in patients with systemic lupus erythematosus patients and arthritis of the fonger joints Ann. Rheum. Dis. 63 Suppl 1 2004 227 (Abst Thu 0404)
209. D.A. Horwitz, D.J. Gray, and S.G. Zheng The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases Arthritis Res 4 2002 241 246
210. K. Nakumura, A. Kitani, and W. Strober Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta J. Exp. Med. 194 2001 629 644
211. W. Chen, W. Jin, H. Tian, P. Sicurello, M. Frank, and J.M. Orenstein Requirement for transforming growth factor beta 1 in controlling T cell apoptosis J. Exp. Med. 194 2001 439 453
212. S.G. Zheng, M.N. Koss, F.P. Quismorio, and D.A. Horwitz Suppression of a lupus-like syndrome with regulatory T cells generated ex-vivo with TGF-β Arthritis Rheum. 44 suppl 2001 S283
213. K. Ohtsuka, J.D. Gray, M.M. Stimmler, and D.A. Horwitz The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity Lupus 8 1999 90 94
214. E. Raz, J. Dudler, M. Lotz, S.M. Baird, C.C. Berry, and R.A. Eisenberg Modulation of disease activity in murine systemic lupus erythematosus by cytokinic gene delivery Lupus 4 1995 286 292
215. M.L. Huggins, F.P. Huang, D. Xu, G. Lindop, and D.I. Stott Modulation of auto-immune disease in the MRL/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier Lupus 8 1999 29 38
216. R.A. Mageed, and G.J. Prud'homme Immunopathology and the gene therapy of lupus Gene Ther 10 2003 861 874
217. K. Yamamoto, and D.J. Loskutoff Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis Lab. Invest. 80 2000 1561 1570
218. E.E. Solomou, Y.T. Juang, M.F. Gourley, G.M. Kammer, and G.C. Tsokos Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus J. Immunol. 166 2001 4216 4222
219. K. Tenbrock, Y.T. Juang, M.F. Gourley, M.P. Nambiar, and G.C. Tsokos Antisense cyclic adenosine 5'-monophosphate response element modulator up-regulated IL-2 in T cells from patients with systemic lupus erythematosus J. Immunol. 169 2002 4147 4152
220. J.C. Gutierrez-Ramos, J.L. Andreu, Y. Revilla, E. Vinuela, and C. Martinez Recovery from auto-immunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus Nature 346 1990 271 274
221. V.A. Illera, C.E. Perandones, L.L. Stunz, D.A. Mower Jr., and R.F. Ashman Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4 J. Immunol. 151 1993 2965 2973
222. M.L. Santiago, L. Fossati, C. Jacquet, W. Muller, S. Izui, and L. Reininger Interleukin-4 protects againts a genetically linked lupus-like auto-immune syndrome J. Exp. Med. 185 1997 65 70
223. R.R. Singh, V. Saxena, S. Zang, L. Li, F.D. Finkelman, and D.P. Witte Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis J. Immunol. 170 2003 4818 4825
224. V. Rus, S.P. Atamas, V. Shustova, I.G. Luzina, F. Selaru, and L.S. Magder Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array Clin. Immunol. 102 2002 283 290
225. S. Feinglass, and A. Deodhar Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11 Arthritis Rheum. 44 2001 170 175
226. F. Zare, M. Bokarewa, N. Nenomen, T. Bergström, L. Alexopoulou, and R.A. Flavel Arthritogenic properties of double-standed (viral) RNA J. Immunol. 172 2004 5656 5663
227. C. Pasare, and R. Medzhitov Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells Science 299 2003 1033 1036
228. E.A. Leadbetter, I.R. Rifkin, A.M. Hohlbaum, B.C. Beaudette, M.J. Shlomchik, and A. Marshak-Rothstein Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors Nature 416 2002 603 607
229. H. Song, X. Nie, S. Basu, and J. Cerny Antibody feedback and somatic mutation in B cells: regulation of mutation by immune complexes with IgG antibody Immunol. Rev. 162 1998 211 218
230. H.T. Ichikawa, L.P. Williams, and B.M. Segal Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates auto-immune disease J. Immunol. 169 2002 2781 2787
231. I. Caramalho, T. Lopes-Carvalho, D. Ostler, S. Zelenay, M. Haury, and J. Demengeot Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide J. Exp. Med. 197 2003 403 411
232. P.P. Ho, P. Fontoura, P.J. Ruiz, L. Steinman, and H. Garren An immunomodulatory GpG oligonucleotide for the treatment of auto-immunity via the innate and adaptive immune systems J. Immunol. 171 2003 4920 4926
233. J.A. Lawton, and P. Ghosh Novel therapeutic strategies based on toll-like receptor signalling Curr. Opin. Chem. Biol. 7 2003 446 451
234. S. Shimizu, H. Nakashima, Y. Inoue, K. Masutani, K. Miyake, and M. Akahoshi Anti-monocyte chemoattractant protein-1 gene therapy glomerulonephritis in the MRL/lpr mice Arthritis Rheum. 46 suppl 2002 S293 Abst 729
235. M. Yamada, H. Yagita, H. Inoue, T. Takanashi, H. Matsuda, and E. Munechika Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritis Arthritis Rheum. 46 2002 735 740
236. S. Ghosh, E. Goldin, F.H. Gordon, H.A. Malchow, J. Rask-Madsen, and P. Rutgeerts Natalizumab for active Crohn's disease N. Engl. J. Med. 348 2003 24 32
237. D.H. Miller, O.A. Khan, W.A. Sheremata, L.D. Blumhardt, G.P. Rice, and M.A. Libonati A controlled trial of Natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 348 2003 15 23
238. L. Farkas, K. Beiske, F. Lund-Johansen, P. Brandtzaeg, and F.L. Jahnsen Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions Am. J. Pathol. 159 2001 237 243
239. S.L. Peng, S.J. Szabo, and L.H. Glimcher T-bet regulated IgG class switching and pathogenic autoantibody production Proc. Natl. Acad. Sci. USA 99 2002 5545 5550
240. M. Fleck, H.G. Zhang, E.R. Kern, H.C. Hsu, R. Muller-Laden, and J.D. Mountz Treatment of chronic sialadenitis in a murin model of Sjögren's syndrome by local Fas L gene transfer Arthritis Rheum. 44 2001 964 973
241. N.M. Hong, K. Masuko-Hongo, H. Sasakawa, T. Kato, T. Shirai, and K. Okumura Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer J. Auto-immun 11 1998 301 307
242. Z. Liu, X. Xu, H.C. Hsu, A. Tousson, P.A. Yang, and Q. Wu CII-DC-Ad TRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis J. Clin. Invest. 112 2003 1332 1341
243. J. Wu, J. Wilson, J. He, L. Xiang, P.H. Schur, and J.D. Mountz Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease J. Clin. Invest. 98 1996 1107 1113
244. L. Prokunina, C. Castillejo-Lopez, F. Oberg, I. Gunnarsson, L. Berg, and V. Magnusson A regulatory polymorphism in PDCD1 is associated with susceptibility ot systemic lupus erythematosus in humans Nat. Genet. 32 2002 666 669
245. L. Xu, L. Zhang, Y. Yi, H.K. Kang, and S.K. Datta Human lupus T cells resist inactivation and escape death by upregulating COX-2 Nat. Med. 10 2004 411 415
246. C. Zoja, A. Benigni, M. Noris, D. Corna, F. Casiraghi, and M. Pagnoncelli Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis Kidney Int. 60 2001 653 663
247. F. Niculescu, P. Nguyen, T. Niculescu, H. Rus, V. Rus, and C.S. Via Pathogenic T cells in murine lupus exhibit spontaneous signaling activity through phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways Arthritis Rheum. 48 2003 1071 1079
248. P.S. Changelian, M.E. Flanagan, D.J. Ball, C.R. Kent, K.S. Magnuson, and W.H. Martin Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 302 2003 875 878
249. S. Pendse, M.H. Sayegh, and M.H. Frank P-glycoprotein - a novel therapeutic target for immunomodulation in clinical transplantation and auto-immunity? Curr. Drug Targets 4 2003 469 476
250. R.H. Weisbarth, R. Baldwin, B. Huh, D.J. Zack, and R. Nishimura Novel protein transcription of primary rat cortical neurons using an antibody that penetrates living cells J. Immunol. 164 2001 6020 6026